Forward-Looking Statements

Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning of applicable securities laws, including, among others, statements concerning Crescita Therapeutics Inc.’s (“Crescita” or the “Company”) objectives and strategies to achieve those objectives, sales of the Company’s products, the Company’s product candidates and the timeline for their development and commercialization, the Company’s future financial condition and performance, potential acquisition and licensing transactions, as well as other statements with respect to management’s beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts.

Such forward-looking information reflect management’s current beliefs as of the date hereof and are based on information currently available to management. Although the forward-looking information contained in these materials and to be discussed during this presentation is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.

Forward-looking information is based on the Company’s estimates and assumptions, and is subject to risks and uncertainties, that could cause actual results to differ materially from such forward-looking information, including those described in the Company’s annual information form, management discussion and analysis and other documents filed with Canadian securities regulators, copies of which are available under the Company’s profile at www.sedar.com.

Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Non-IFRS Measures

The Company reports its financial results in accordance with IFRS. However, we use certain non-IFRS financial measures to assess our Company's performance. We believe these to be useful to management, investors and other financial stakeholders in assessing Crescita's performance from both a financial and operational standpoint. The non-IFRS measures used in this presentation do not have any standardized meaning prescribed by IFRS and are therefore not comparable to similar measures presented by other issuers. These measures should be considered as supplemental in nature and not as a substitute for the related financial information prepared in accordance with IFRS found in our continuous disclosure documents.

Adjusted EBITDA is a non-IFRS measure. This term is defined as earnings (loss) before interest, income taxes (recovery), depreciation and amortization, equity-settled stock-based compensation, goodwill and intangible assets impairment, and foreign currency (gains) and losses. Management believes that Adjusted EBITDA is an important measure of operating performance and cash flow and provides useful information to investors as it highlights trends in the underlying business that may not otherwise be apparent when relying solely on IFRS measures.
## Crescita at a Glance

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unique Commercial Dermatology Company</td>
<td>Serving Rx and Non-Rx Markets</td>
</tr>
<tr>
<td>Stock Symbol</td>
<td>TSX: CTX</td>
</tr>
<tr>
<td>2020 Annual Revenue</td>
<td>$15.6M</td>
</tr>
<tr>
<td>Cash Balance</td>
<td>$14.3M</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$17.3M</td>
</tr>
<tr>
<td>Fully Diluted Shares Outstanding</td>
<td>24.9M</td>
</tr>
<tr>
<td>Employees</td>
<td>~70</td>
</tr>
</tbody>
</table>

---

1 As of April 15, 2021. 2 As of December 31, 2020
A Repositioned Company with Clear Strategies to Deliver Profitable Growth

- Strengthened Balance Sheet
- Diversified Asset Portfolio
- Clear Strategic Priorities
- Multiple Growth Catalysts

$14.3M Cash*
Low Debt
Serving Growing Markets
Leveraging Strong Balance Sheet & Portfolio
Path to Sustainable Profitable Growth

As at December 31, 2020
A Repositioned Company with Clear Strategies to Deliver Profitable Growth

1. A Repositioned Crescita
2. Compelling Growth Strategies, Multiple Drivers
3. A Clear Path Forward
A Transformed Business Poised for Profitable Growth

2016-17
Redefined our path
- New leadership team, vision and strategy
- Acquired key assets to strengthen portfolio and infrastructure

2018-20
Repositioned for profitability
- Secured $3.5M LOC*+
  Repaid long-term debt
- Achieved 1st year of profitability in 2018
- Managed through pandemic

2021+
Executing on growth
- Clear strategic priorities
- Leveraging cash position and asset portfolio to accelerate growth

* LOC: Line of Credit
Unique Commercial Dermatology Company

**Non-Rx Market**
- 4 Skincare Brands
- Plant & CDMO* Services

**Rx Market**
- Commercial Product
- RX Product Pipeline

Two Patented Drug Delivery Technologies

---

*Contract Development and Manufacturing Organization

**Note:** Crescita has three reportable segments: Commercial Skincare, Licensing & Royalties, and Manufacturing & Services.
Consumer Macro Trends Favor Crescita’s Rx & Non-Rx Portfolios

- Skincare Spending Up
  Shift in spending from cosmetics

- Millennials
  aging into category

- Growth
  in minimally invasive procedures

- 50+ Consumer
  Desire for more youthful appearance
Growing International Footprint Through Strong Partnerships

Strong Partnerships

USA

cantabria labs

ITALY
FRANCE
SPAIN
PORTUGAL

JUYOU

AUSTRIA

ITALY
FRANCE
SPAIN
PORTUGAL

CHINA

AUSTRIA
Seasoned Management Team with Extensive Experience
Across Cosmetic/Pharma Industry, Operational Excellence, Innovation and Strategic Growth

Serge Verreault
President & CEO
+30 years in pharma and medical industry

Jose DaRocha
Chief Financial Officer
+25 years in cosmetics & pharma

Wade Hull
VP R&D
+20 years in medical device & pharmaceutical development

Isabelle Villeneuve
VP Strategy Quality & Innovation
+30 years in innovation, market intelligence & formulations

Alain Dugal
VP Manufacturing & Logistics
+25 years in operations

Ivonne Medina
VP Business Development
+15 years in business development, licensing & strategic partnerships
FINANCIALS

Strong Performance Record, Diversified Revenue Streams

Revenue
In millions of CAD

Pre-COVID 35% CAGR

2016* 2017 2018 2019 2020
$4 $12 $17 $22 $16

Adjusted EBITDA
In millions of CAD

2016* 2017 2018 2019 2020
($13) $2 $7 $3

Key Profitability Drivers
✓ High margin licensing revenue
✓ Operational excellence
✓ Expense management
✓ Manufacturing utilization & volume increases

2020 Revenue by Segment

Commercial Skincare 43%
Licensing & Royalties 46%
Manufacturing & Services 11%

*Fiscal 2016 reflects 10 months of operations and 4 months of results from INTEGA Skin Sciences Inc. due to the timing of the acquisition.
Solid Balance Sheet Management, Firepower to Fund Growth

- Reduced Debt by >75%
  - 2017: $6.0M
  - 2020: $1.4M*
  - Paid down $3.6M LT debt with Knight Therapeutics Inc.

- Doubled Cash Position
  - 2017: $7.0M
  - 2020: $14.3M
  - >2x increase

- Capital Allocation Priorities
  - Invest in growth via M&A
  - Invest in organic growth (R&D, Sales & Marketing, partnering)
  - Opportunistic share buyback

Total Liquidity of **$17.8M** to Fund Growth

*Total debt obligations represent the sum of the long and short-term portions of long-term debt, convertible debentures, lease and other obligations.
**Total liquidity includes $14.3M in cash and cash equivalents (at December 31, 2020) and a $3.5M credit facility, subject to margin requirements.
A Repositioned Company with Clear Strategies to Deliver Profitable Growth

1. A Repositioned Crescita
2. Compelling Growth Strategies, Multiple Drivers
3. A Clear Path Forward
Compelling Growth Strategies to Unlock Crescita’s Full Potential

1. Expand Pliaglis in ROW
2. Grow Medical Aesthetics Business in Canada
3. Leverage Cash to Pursue Strategic M&A
4. Capitalize on Upside Potential

Strong Foundation
Trusted Partner • Operational Excellence • Track Record of Execution • Experienced Leadership
A Highly Differentiated Rx Topical Anesthetic Responding to a Range of Growing Procedures

Compelling Value Proposition
✓ Better efficacy
✓ Ease of use
✓ Uses Crescita’s Peel technology
✓ Patent protected (Enhanced formulations through 2031)

Used Across Several High-Demand Superficial Dermatological Procedures
✓ Laser-assisted tattoo removal
✓ Non-ablative laser facial resurfacing
✓ Dermal filler injections
✓ Pulsed-dye laser therapy

Only FDA-approved, anesthetic cream with the **HIGHEST CONCENTRATION** of Tetracaine and Lidocaine 7% / 7%

**APPLY**

**PAUSE**

**PEEL**
Profitable Pliaglis Licensing Model

Our track record

Accelerated Returns in the U.S. with Taro Pharmaceuticals

- **Royalties**
  - 2018 to 2020: $12.6M

- **Milestones**
  - Launched in 2018: $6.3M

- **Upfront Payment**
  - Deal signed in 2017: $2.7M

Accretive Multi-EU Country Deal with Cantabria Labs

- **Royalties & Sales Milestones**
  - 2020+ revenue:
    - Net cash impact of **$2.7M** from up-front payments in 2019

*France and Portugal have yet to be launched
STRATEGY # 1
EXPAND PLIAGLIS IN ROW

Significant Potential to Further Monetize Pliaglis in ROW

8 Licensed Countries

3 Countries with Commercial Sales

Royalty streams typically begin 12 to 18 months after deal is signed

USA – ITALY – SPAIN

5 Anticipated Launches

2021 / 22
- Austria
- France
- Mexico
- Portugal

2023+
- China

Untapped Market Potential

18 ROW countries where Pliaglis is approved and available for licensing

+ More countries with approval potential

Upfront payments • Milestones • Royalties
Expanding in an Attractive, Booming Market

Global Medical Aesthetics Market¹ (By 2025)

- Increasing adoption of minimally invasive & non-invasive aesthetic procedures
- Increasing awareness due to social media
- Cosmetic procedures no longer taboo

Hyaluronic Acid Dermal Fillers

Expected to reach US$1.9B by 2025¹
CAGR +11.3%

Expected to reach US$190M by 2025²

15M Cosmetic procedures performed in the U.S each year, 89% were non-surgical³

Two Innovative and On-Trend Product Launches
Address Increasing Popularity of Aesthetic Procedures

**Gold Standard in Bio-Revitalization**

**Uses:** Topical skin quality & replenishing protocol
- Unique formula with Hyaluronic Acid (HA) and 50+ key ingredients
- >4M bottles sold in >60 countries in 2020
- 10 years of clinical efficacy and safety data

**NCTF® Boost 135 HA**
New Cellular Treatment Factor

**Haute Sculpture Dermal Filler**

**Uses:** Restore volume, contours, temporarily eliminate wrinkles and volumizes lips
- Exclusive collection of five HA-based fillers
- Widely used in >60 markets

**First and Exclusive Distributor in Canada**
Clear Go-to-Market Strategies to Accelerate Product Launches

1. Leverage established, integrated commercial Canadian infrastructure (activate in-clinic trials, grow existing accounts)

2. Offer differentiated products in the Canadian medical aesthetic market with the successful launch of NCTF & ART-FILLER

3. Increase # of medical accounts and engage directly with consumers to boost treatment requests
Actively Targeting a Strategic Acquisition to Accelerate Profitable Growth
Focused on Rx & Non-Rx Opportunities

Financial Criteria
✓ Topline of $5-25M CAD
✓ Accretive to EBITDA
✓ Synergistic

Strategic Business Fit
✓ Aesthetic or medical aesthetic field
✓ Growing and on-trend brands
✓ Adds strategic capabilities
✓ Prescription dermatology

$14M Cash
Other Growth Plays Provide Additional Upside Potential

**STRATEGY # 4**

**CAPITALIZE ON UPSIDE POTENTIAL**

**E-Commerce**
- Reach Awareness Conversion
- Direct-to-consumers digital marketing campaign
- Strengthen partnership with aestheticians

**Manufacturing & Services**
- **+48%**
  2017-2019 CAGR*
- **75%**
  unutilized capacity

- **Add volume to grow profits**
  - Grow customer base
  - Increase unused capacity without increasing costs
  - Improved plant efficiency

**Rx Pipeline**
- **CTX-101 (PH3)**
  - indicated for plaque psoriasis
- **CTX-102 (PH2)**
  - undisclosed indication
- Joint venture with 2 U.S. partners. CTX % of revenues
- Licensing discussions in progress

**Build B2C revenue stream**

**Potential recurring licensing revenue**

---

*CAGR was calculated using 2019 results to exclude the impact of COVID-19 on our Manufacturing & Services segment.*
A Repositioned Company with Clear Strategies to Deliver Profitable Growth

1. A Repositioned Crescita
2. Compelling Growth Strategies, Multiple Drivers
3. A Clear Path Forward
Key Milestones to Track our Progress through 2022

- Pliaglis ROW launches
  - (Austria, France, Portugal, Mexico)
- Sign profitable Pliaglis licensing deals in ROW
- Successfully launch NCTF® and ART-FILLER®
- Disciplined evaluation of M&A targets
- Grow Canadian Dermo-Cosmetic sales
- Grow CDMO business
A Repositioned Company with Clear Strategies to Deliver Profitable Growth

- Strengthened Balance Sheet
- Diversified Asset Portfolio
- Clear Strategic Priorities
- Multiple Growth Catalysts

$14.3M Cash*
Low Debt
Serving Growing Markets
Leveraging Strong Balance Sheet & Portfolio
Path to Sustainable Profitable Growth

As at December 31, 2020